1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Equipment & Services
Profusa, Inc. Common Stock

Profusa, Inc. Common Stock

PFSA
Profusa, Inc. Common StockUS flagNASDAQ Global Market
0.32
USD
-0.01
- -
176,280.00Market Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-23.58
-46.24
-23.52
-21.11
-107.01
-49.93
Free Cash Flow per Basic Share
-24.45
-17.62
-10.07
-4.73
-48.56
-21.53
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-194.95
-241.2
-264.71
-285.82
-480.28
-193.34
Tangible Book Value per Share
-191.35
-228.21
-251.6
-272.66
-79.63
-33.2
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
1
1
- -
- -
- -
- -
Net Income, GAAP
-10
-20
-10
-9
-36
-42
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
-21
-35
-46
-57
-18
-28
LT Debt
8
- -
- -
- -
8
- -
Total Equity
-84
-100
-110
-119
-27
-28
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7
7
13
LT Borrowings
14
8
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
4
Market Capitalization
10
3
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
4
4
1
Cash, Cash Equivalents & STI
3
2
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
24
22
29
Payables & Accruals
13
11
12
ST Debt
7
7
13
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-77.64%
Free Cash Flow
- -
- -
686.83%
Net Income, GAAP
- -
- -
288.11%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.46
-0.91
-5.71
- -
-21.11
2025
-6.21
-18.75
-52.45
- -
-107.01
2026
-2.05
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Ben Chung-Bin Hwang
Full Time Employees
2
Sector
Healthcare
Industry
Medical - Equipment & Services
Address
5959 Horton Street, Suite 450, Emeryville, CA 94608 EmeryVille CA United States of America 94608
IPO Date
Jul 14, 2025
CIK
0001859807
Website
profusa.com
Similar Companies
Brainaurora-b (6681.HK)
Profusa, Inc. Common Stock (PFSA)
Meridian Bioscience, Inc. (0K0K.L)
Nexus AG (0FGL.L)
UBC Medical Indonesia Tbk. (LABS.JK)
Cambria Automobiles plc (CAMB.L)
Business
Profusa, Inc. is a digital health innovator engineering advanced tissue-integrated biosensors to consistently track an individual's internal body chemistry, delivering intelligent, data-driven health insights for managing long-term conditions. The company's Lumee™ Oxygen Platform, which has received CE Mark approval for European use, employs micro-sensors and optical readers to provide real-time tissue oxygen levels, addressing needs in peripheral artery disease, chronic wounds, and reconstructive surgery. Profusa is also progressing toward a continuous glucose monitoring system for diabetes management, aiming to harness AI for personalized medical data directly from within the body to inform treatment and improve outcomes.

Company News

APIChat

  • globenewswire.com

    Profusa Announces Listing Transfer to The Nasdaq Capital Market

  • globenewswire.com

    Profusa Receives Favorable Nasdaq Listing Determination

  • globenewswire.com

    Profusa Receives Favorable Nasdaq Listing Determination

  • globenewswire.com

    Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

  • feeds.benzinga.com

    What's Going On With Profusa Stock Tuesday?

  • globenewswire.com

    Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

  • feeds.benzinga.com

    Why Applied Optoelectronics Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

  • defenseworld.net

    Analyzing Profusa (NASDAQ:PFSA) & Medline (NASDAQ:MDLN)

  • globenewswire.com

    Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

  • defenseworld.net

    CapsoVision (NASDAQ:CV) and Profusa (NASDAQ:PFSA) Head-To-Head Review

  • defenseworld.net

    Head to Head Comparison: Profusa (NASDAQ:PFSA) versus Predictive Oncology (NASDAQ:AGPU)

  • globenewswire.com

    Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance

  • globenewswire.com

    Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

  • defenseworld.net

    Critical Comparison: Nanovibronix (NASDAQ:FEED) versus Profusa (NASDAQ:PFSA)

  • defenseworld.net

    Head to Head Comparison: Nanovibronix (NASDAQ:FEED) vs. Profusa (NASDAQ:PFSA)

  • globenewswire.com

    Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

  • defenseworld.net

    Head-To-Head Review: Profusa (NASDAQ:PFSA) versus Carlsmed (NASDAQ:CARL)

  • defenseworld.net

    Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast

  • globenewswire.com

    Profusa Announces 1-for-75 Reverse Stock Split

  • globenewswire.com

    Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026